株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病の世界市場の分析:考察、動向、予測

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

発行 Koncept Analytics 商品コード 879100
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.71円で換算しております。
Back to Top
血友病の世界市場の分析:考察、動向、予測 Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)
出版日: 2019年07月01日 ページ情報: 英文 106 Pages
概要

当レポートでは、世界の血友病市場について分析し、疾患の概要や主な診断・治療法、世界全体の市場規模 - 患者数、治療薬の売上高 - の動向見通し (種類別、重症度別、治療の種類別、治療計画別)、地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどを調査しております。

第1章 市場概要

  • 血友病とは
  • 血友病の種類
  • 徴候・症状
  • 血友病の診断方法
  • 血友病の治療方法

第2章 世界市場の分析

  • 市場規模 (金額ベース)
  • 市場規模の予測値 (金額ベース)
  • 市場規模:レジメン (治療計画) 別
  • 市場規模:種類別
    • 血友病A市場の予測値 (金額ベース)
    • 血友病A市場:重症度別
    • 血友病A市場:治療の種類別 (予防/対処療法)
    • 血友病A市場:レジメン別
    • 血友病B市場の予測値 (金額ベース)
    • 血友病B市場:重症度別
    • 血友病B市場:治療の種類別
    • 血友病B市場:レジメン別

第3章 地域市場の分析

  • 米国
    • 市場規模 (金額ベース)
    • 市場規模の予測値 (金額ベース)
    • 市場規模:種類別 (金額ベース)
    • 市場規模の予測値:種類別 (金額ベース)
    • 血友病A市場 - 治療済み患者数の予測値
    • 血友病A市場 - 予防治療中の重症患者数
    • 血友病A市場 - 対処療法中の重症患者数
    • 血友病A市場 - 予防治療中の軽症・中症患者数
    • 血友病A市場 - 対処療法中の軽症・中症患者数
    • 血友病B市場 - 治療済み患者数の予測値
    • 血友病B市場 - 予防治療中の重症患者数
    • 血友病B市場 - 対処療法中の重症患者数
    • 血友病B市場 - 予防治療中の軽症・中症患者数
    • 血友病B市場 - 対処対処療中の軽症・中症患者数
  • 欧州
    • 血友病市場:患者数の予測値
    • 血友病A市場:患者数の予測値
    • 血友病B市場:患者数の予測値

第4章 市場のダイナミクス

  • 成長促進要因
  • 市場の主な傾向と機会
  • 課題

第5章 競争環境

  • 世界市場
    • 血友病A:企業別市場シェア
    • 血友病A向け第VIII因子:製品別市場シェア
    • 血友病A向け第VIII因子遺伝子療法:市場シェア、予測値
    • 血友病B:企業別市場シェア
    • 血友病B向け第IX因子:製品別市場シェア、予測値
    • 血友病B向け第IX因子遺伝子療法:市場シェア、予測値
  • 米国市場
    • 血友病A市場:企業別市場シェア
  • 欧州市場
    • 血友病A市場:企業別市場シェア

第6章 企業プロファイル

  • Pfizer Inc.
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • Bayer Group
  • Sanofi S.A.
  • 武田薬品工業
  • Novo Nordisk
  • CSL Limited
目次

The global hemophilia market is estimated to reach US$12.98 billion in 2023, holding a CAGR of 6.21% in the duration spanning 2018-2023. The factors such as rise in diagnoses rate of hemophilia, rise in global healthcare expenditure and shifting focus to extended half-life (EHL) therapies are expected to drive the growth of the global hemophilia market. However, growth of the industry will be challenged by high price of treatment and reluctance to switch to new therapies. A few notable trends include shifting focus to Extended Half Life (EHL) therapies, development of novel hemophilia treatments and popularity of gene therapy.

The global hemophilia market comprises of two major segments: hemophilia A and hemophilia B. hemophilia A is four time prevalent than hemophilia B. The growing incidences of hemophilia A at vast rate has driven the increased demand for anti-hemophilia A or clotting factor VIII drugs. The pharmaceutical industry is flooded with drugs to be used in the treatment of type A, and thereby providing scope for the expansion of the global hemophilia market.

The fastest growing regional market in the hemophilia space is the U.S. due to High prevalence of hemophilia, coupled with rising inclination toward prophylaxis treatment. Rise in the population of hemophilia patients, is augmenting the need for more significant treatment methods. A lot of anti-hemophilia products are available in the market and several drugs are still in their late stage clinical process by large pharmaceutical firms. Furthermore, The U.S. and Europe are the highly established premium markets that contribute to considerable shares in the global hemophilia market.

Scope of the report:

The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.

The major regional markets (the U.S. and Europe) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • Raw Material Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis of Hemophilia
  • 1.5 Treatment of Hemophilia

2. Global Market Analysis

  • 2.1 Global Hemophilia Market by Value
  • 2.2 Global Hemophilia Market Forecast by Value
  • 2.3 Global Hemophilia Market by Treatment Regimen
  • 2.4 Global Hemophilia Market by Type
    • 2.4.1 Global Hemophilia A Market Forecast by Value
    • 2.4.2 Global Hemophilia A Market by Severity
    • 2.4.3 Global Hemophilia A Market by Treatment Type
    • 2.4.4 Global Hemophilia A Market by Treatment Regimen
    • 2.4.5 Global Hemophilia B Market Forecast by Value
    • 2.4.6 Global Hemophilia B Market by Severity
    • 2.4.7 Global Hemophilia B Market by Treatment Type
    • 2.4.8 Global Hemophilia B Market by Treatment Regimen

3. Regional Market Analysis

  • 3.1 The U.S.
    • 3.1.1 The U.S. Hemophilia Market by Value
    • 3.1.2 The U.S. Hemophilia Market Forecast by Value
    • 3.1.3 The U.S. Hemophilia Market by Type
    • 3.1.4 The U.S. Hemophilia A Market Forecast by Value
    • 3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
    • 3.1.6 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
    • 3.1.7 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
    • 3.1.8 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
    • 3.1.10 The US Hemophilia B Market Forecast by Value
    • 3.1.11 The US Hemophilia B Market- Treated Patients Volume Forecast
    • 3.1.12 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
    • 3.1.13 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
    • 3.1.14 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
  • 3.2 Europe
    • 3.2.1 Europe's Hemophilia Market- Patient Volume Forecast
    • 3.2.2 Europe's Hemophilia A Market- Patient Volume Forecast
    • 3.2.3 Europe's Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increased Focus on Prophylactic Treatment
    • 4.1.2 Increasing Diagnosis Rate
    • 4.1.3 Rise in Global Healthcare Expenditure
  • 4.2 Key Trends & Development
    • 4.2.1 Shifting Focus to Extended Half Life Therapies
    • 4.2.2 Development of Novel Hemophilia Treatments
    • 4.2.3 Popularity of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape

  • 5.1 The Global Market
    • 5.1.1 Global Hemophilia A Market Share by Company
    • 5.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
    • 5.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
    • 5.1.4 Global Hemophilia B Market Share by Company
    • 5.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
    • 5.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
    • 5.1.7 Key Players - Main Anti-Hemophilia Products
    • 5.1.8 Key Players - Revenue Comparison
    • 5.1.9 Key Players - Market Capital Comparison
  • 5.2 The U.S. Market
  • The U.S. Hemophilia A Market Share by Company
  • 5.3 Europe Market
  • Europe Hemophilia A Market Share by Company

6. Company Profiles

  • 6.1 Pfizer Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Bayer Group
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Sanofi S.A.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Takeda Pharmaceutical Company
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Novo Nordisk
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 CSL Limited
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Hemophilia Market by Value (2014-2018)
  • Global Hemophilia Market Forecast by Value (2019-2023)
  • Global Hemophilia Market by Treatment Regimen (2018)
  • Global Hemophilia Market by Type (2018)
  • Global Hemophilia A Market Forecast by Value (2018-2023)
  • Global Hemophilia A Market by Severity (2018)
  • Global Hemophilia A Market by Treatment Type (2018)
  • Global Hemophilia A Market by Treatment Regimen (2018/2023)
  • Global Hemophilia B Market Forecast by Value (2018-2023)
  • Global Hemophilia B Market by Severity (2018)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2018/2023)
  • The U.S. Hemophilia Market by Value (2014-2018)
  • The U.S. Hemophilia Market Forecast by Value (2019-2023)
  • The U.S. Hemophilia Market by Type (2018)
  • The U.S. Hemophilia A Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia A Market-Treated Patient Volume Forecast (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on Prophylactic Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia B Market- Treated Patients Volume Forecast (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • Europe's Hemophilia Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia A Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia B Market- Patient Volume Forecast (2018-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2018)
  • Global Identified Hemophilia Patients Volume (2011-2018)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2017)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2017)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2022/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2018)
  • Europe Hemophilia B Market Share by Company (2018)
  • Pfizer Inc. Revenue Share by Major Business Segment (2018)
  • Pfizer Inc. Revenue and Net Income (2014-2018)
  • Pfizer Inc. R&D Expenses (2016-2018)
  • Bayer Group Net Sales Share by Business Segments (2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group R&D Expenses (2016-2018)
  • Sanofi S.A. Revenue Share by Segments (2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. R&D Expenses (2016-2018)
  • Takeda Pharmaceutical Company Revenue Share by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2015-2019)
  • Takeda Pharmaceutical Company R&D Expenses (2017-2019)
  • Novo Nordisk Net Sales Share by Business Segments (2018)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk R&D Expenses (2016-2018)
  • CSL Limited Revenue Share by Segments (2018)
  • CSL Limited Sales Revenue and Net Profit (2014-2019)
  • CSL Limited R&D Expenses (2016-2018)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2018)
  • Development of New Novel Hemophilia Treatments (2018)
  • Hemophilia Gene Therapy Candidates (2018)
  • Key Players - Main Anti-Hemophilia Products
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Capital Comparison (2019)
  • Major Products Developed by Pfizer Inc. (2018)
  • Major Products Developed by Bayer Group (2018)
  • Novo Nordisk Product Pipeline (2018)
Back to Top